The forecast for the Japanese market for hormones in dosage, excluding contraceptives and antibiotics, indicates a declining trend from $5.0176 billion in 2024 to $4.8918 billion in 2028. This represents an average annual drop, or compound annual growth rate (CAGR), of approximately 0.63% over the five-year period. In 2023, the market was slightly above $5 billion, showing a modest downward trajectory into the forecasts of the subsequent years. The year-on-year variations indicate smaller declining percentages, emphasizing a slow but consistent descent in market value.

Future Trends to Watch:

Advancements in hormone therapy technology could reverse the declining trend, especially if new applications are discovered.
Regulatory changes or healthcare reforms in Japan that affect medication pricing or insurance could impact market dynamics.
Increased focus on personalized medicine may shift consumer preferences, influencing market demand.
Potential influence of demographic changes, such as an aging population, on the demand for hormone treatments.